
|Videos|March 17, 2021
Refining Combination Strategies in Metastatic RCC
Author(s)Toni K. Choueiri, MD, Robert J. Motzer, MD
Drs Toni Choueiri and Robert J. Motzer reflect on recent data supporting the use of TKI/I-O combination regimens for frontline treatment of metastatic renal cell carcinoma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Accepts NDA for Daraxonrasib in Pretreated Metastatic Pancreatic Cancer
2
CAR T-Cell Expansion Predicts Toxicity, But Not Always Efficacy
3
Mapping the Full CAR T-Cell Journey in DLBCL From Referral to Survivorship
4
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
5





















































